Drug Discovery@nature.com 05 April 2013

TABLE OF CONTENTS 5 April 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   News Top Antibody drugs set to revive flagging migraine target doi:10.1038/nrd3991 CGRP makes a comeback as antibodies advance into Phase II trials. Full Text Molecular imaging as a de-risking tool: coming into focus? doi:10.1038/nrd3993 Molecular imaging is already engrained in early-stage trials for central nervous system disorders, but used infrequently in other therapeutic areas. What will it take to make it standard practice across the pipeline? Full Text Anticancer IGF1R classes take more knocks doi:10.1038/nrd3992 Disappointing developments with Amgen's ganitumab and Bristol-Myers Squibb's BMS-754807 highlight the need for rational combinations and predictive biomarkers to rescue IGF1R pathway antagonists. Full Text Market watch: Upcoming market catalysts in Q2 2013 doi:10.1038/nrd3990 Notable market catalysts expected in the second quarter of 2013 include initial Phase III results for SAR302503 in myelofibrosis and first data from the Phase III rheumatoid arthritis programme for fostamatinib. Full Text Analysis Top Bromodomains on the brain doi:10.1038/scibx.2013.277 MYCN amplification provides a marker for sensitivity to BET bromodomain inhibition in neuroblastomas. GSK is using the marker as one criterion to select patients for a Phase I trial of its BET bromodomain inhibitor in cancer. Full Text Antibody–drug conjugates doi:10.1038/nrd3980 Antibody–drug conjugates (ADCs), which allow cytotoxic drugs to be selectively targeted to cancer cells, are attracting considerable interest. This article analyses the ADC pipeline, as well as trends in collaborations and deals related to ADC platforms. Full Text Research Highlights Top Metabolic disorders: Breaking the links between inflammation and diabetes doi:10.1038/nrd3988 Two papers identify approaches to inhibit the activity of the NF-κB pathway, which improved obesity-associated metabolic dysfunctions in mouse models Full Text Blood disorders: Epigenetically enhancing haemoglobin production doi:10.1038/nrd3998 Inhibition of lysine-specific demethylase 1 could be a promising approach for inducing γ-globin synthesis to treat β-globinopathies. Full Text Nanotechnology: Biological proteins knock nanoparticles off target doi:10.1038/nrd3983 Proteins present in biological serum can shield targeted nanoparticles from their intended target. Full Text Research & Reviews Top Adenosine receptors as drug targets — what are the challenges? doi:10.1038/nrd3955 Fredholm and colleagues provide an overview of the physiological and pathological functions of adenosine and consider the challenges in the development of compounds targeting adenosine receptors. Full Text Challenges and approaches for the development of safer immunomodulatory biologics doi:10.1038/nrd3974 This article discusses strategies to predict and mitigate adverse effects of immunomodulatory biologics, such as infections and cytokine release syndrome, and considers how they can be used to inform the development of safer drugs. Full Text Target identification and mechanism of action in chemical biology and drug discovery doi:10.1038/nchembio.1199 This review discusses approaches to target identification such as direct biochemical methods, genetic interactions and computational inference, and how they may be combined to characterize on-target and off-target effects and to understand mechanisms of action of small molecules. Full Text The why and how of phenotypic small-molecule screens doi:10.1038/nchembio.1206 This article discusses the basic principles underlying the design of phenotypic screens and proposes guidelines to facilitate the discovery of small molecules from them. Full Text Drug Discovery JOBS of the week PhD Studentship in Cheminformatics / Computer-Aided Drug Design in Cambridge / UK University of Cambridge Head of Research Delivery & Post Award Management Arthrisits Research UK Post Doc m / f CardioMetabolic Diseases Research Boehringer Ingelheim Pharma GmbH & Co. KG More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 12.09.13 Cambridge - UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.